IP Library Granted Patent US 8,729,127
Granted Patent B2
US 8,729,127 · App. 13/024,681 · Granted May 20, 2014

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders

Inventors: Michael Graeber (Lawrenceville, NJ); Janusz Czernielewski (Biot, FR)
Assignee: Galderma Research & Development
A61K9/0014A61K31/07A61K31/203A61K47/48784C07C2103/74Y10S514/859
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,729,127
App. No.
13/024,681
Granted
May 20, 2014
Kind
B2
Abstract

Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Claims (16)

1. A method for eliciting an early onset of action in regression of non-inflammatory lesions or regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, wherein said early onset of action occurs by one week after treatment begins and is demonstrated by regression of non-inflammatory lesions or regression of total acne lesions greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after one week of treatment.

2. The method according to claim 1 , wherein the common acne is of moderate to moderately severe intensity.

3. The method according to claim 1 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

4. The method according to claim 1 , wherein the composition comprises a gel.

5. The method according to claim 2 , wherein the composition comprises a gel.

6. A method for eliciting an early onset of action in regression of non-inflammatory lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by one week after treatment begins and being demonstrated by regression of non-inflammatory lesions after one week of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after one week of treatment.

7. The method according to claim 6 , wherein the common acne is of moderate to moderately severe intensity.

8. The method according to claim 6 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

9. The method according to claim 7 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

10. The method according to claim 6 , wherein the composition comprises a gel.

11. The method according to claim 7 , wherein the composition comprises a gel.

12. A method for eliciting an early onset of action in regression of total acne lesions in treating common acne afflicting an individual's skin, the individual being in need of such treatment, comprising topically administering daily to said individual an anti-acne effective amount of a pharmaceutical composition which comprises 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into a pharmaceutically acceptable medium therefor, said composition being a gel or a cream, said early onset of action occurring by one week after treatment begins and being demonstrated by regression of total acne lesions after one week of treatment greater than that demonstrated by vehicle alone or by a similar composition comprising 0.1% by weight of adapalene after one week of treatment.

13. The method according to claim 12 , wherein the common acne is of moderate to moderately severe intensity.

14. The method according to claim 12 , wherein the composition comprises a gel.

15. The method according to claim 13 , wherein the composition comprises a gel.

16. The method according to claim 12 , wherein the composition is a gel comprising adapalene, carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide and purified water.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2014
From: GRAEBER, MICHAEL; CZERNIELEWSKI, JANUSZ
To: GALDERMA RESEARCH & DEVELOPMENT
Reel/Frame 032294/0778 →
Priority Claims (1)
FR 02 03070 · Mar 12, 2002 · national
Continuity (6)
Continuation 12902972 · Oct 12, 2010
Continuation 12437008 · May 7, 2009
Continuation 10937612 · Sep 10, 2004
Continuation PCTEP0303246 · Mar 12, 2003
Provisional Application 60370223 · Apr 8, 2002
Related Publication 20110130461A1 · Jun 2, 2011